On Nov 08, major Wall Street analysts update their ratings for $Moderna (MRNA.US)$, with price targets ranging from $55 to $111.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $70.
BofA Securities analyst Alec Stranahan maintains with a hold rating, and adjusts the target price from $110 to $90.
Barclays analyst Gena Wang maintains with a buy rating, and adjusts the target price from $125 to $111.
TD Cowen analyst Tyler Van Buren maintains with a hold rating, and adjusts the target price from $60 to $55.
Needham analyst Joseph Stringer maintains with a hold rating.
Furthermore, according to the comprehensive report, the opinions of $Moderna (MRNA.US)$'s main analysts recently are as follows:
Moderna's Q3 SpikeVax revenue exceeded expectations, and the company has maintained its previously issued guidance. Despite this, a cautious outlook has been presented for 2025, which could be influenced by the anticipated approval of two additional vaccines.
Moderna's recent performance, which exceeded expectations in COVID vaccine sales, was partly due to the earlier commencement of the vaccination season compared to the previous year. Nevertheless, the company has adjusted its projection for vaccination rates for the year from initially expecting them to be consistent with last year's to now anticipating a possible decline of up to 10%. It was also mentioned that while the revenue forecast for the year has been maintained, the company anticipates results to be towards the lower end of the previously stated range.
Here are the latest investment ratings and price targets for $Moderna (MRNA.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间11月8日，多家华尔街大行更新了$Moderna (MRNA.US)$的评级，目标价介于55美元至111美元。
摩根士丹利分析师Terence Flynn维持持有评级，维持目标价70美元。
美银证券分析师Alec Stranahan维持持有评级，并将目标价从110美元下调至90美元。
巴克莱银行分析师Gena Wang维持买入评级，并将目标价从125美元下调至111美元。
TD Cowen分析师Tyler Van Buren维持持有评级，并将目标价从60美元下调至55美元。
Needham分析师Joseph Stringer维持持有评级。
此外，综合报道，$Moderna (MRNA.US)$近期主要分析师观点如下：
modernah在Q3的SpikeVax营业收入超出预期，公司已保持先前提出的指导方针。尽管如此，对2025年提出了谨慎的展望，这可能会受到预期中的两种额外生物-疫苗批准的影响。
modernah最近的表现超出了COVID疫苗销售的预期，部分原因是较前一年疫苗接种季节早。然而，该公司已调整了对今年疫苗接种率的预测，最初预期与去年持平，现在预计可能下降最多10%。还提到，尽管今年的营业收入预测已保持不变，但公司预计结果将位于先前区间范围的下限。
以下为今日6位分析师对$Moderna (MRNA.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
